New drug Fx-5A takes first step toward fighting heart disease

NCT ID NCT04216342

Recruiting now Knowledge-focused Sponsor: National Heart, Lung, and Blood Institute (NHLBI) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 16, 2026 · Updated 3 times

Summary

This study tests whether a new drug called Fx-5A is safe in healthy adults. Researchers will give a single infusion of the drug and monitor participants for side effects. The goal is to see if Fx-5A can be used in future studies for heart disease and inflammation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Fx-5A peptide complex
What this could lead to: If safe, this could pave the way for a new treatment for heart disease and inflammation.
What could go wrong: This is a very early, small study in healthy people, not patients. The drug may not work or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIOVASCULAR DISEASE

Contacts and locations

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.